Literature DB >> 26723186

Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma.

Edmund C P Chedgy1, Peter C Black1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26723186     DOI： 10.1016/j.urology.2015.12.003

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  3 in total

Review 1.  New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy.

Authors:  Kevin Zarrabi; Chunhui Fang; Shenhong Wu
Journal:  J Hematol Oncol       Date:  2017-02-02       Impact factor: 17.388

Review 2.  Emerging therapeutic agents for genitourinary cancers.

Authors:  Kevin Zarrabi; Azzam Paroya; Shenhong Wu
Journal:  J Hematol Oncol       Date:  2019-09-04       Impact factor: 17.388

Review 3.  PD-1 Inhibitors in the Advanced Esophageal Cancer.

Authors:  Ye Hong; Zhen-Yu Ding
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.